Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma

NCT02454179 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

78

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG: pembrolizumab
DRUG: Acalabrutinib

Sponsor

Acerta Pharma BV

Collaborators

[object Object]